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ABSTRACT
Background: Transcription factor 7-like 2 (TCF7L2) rs7903146
associates with type 2 diabetes and may operate via impaired
glucagon-like peptide 1 secretion, which is stimulated more by fat
than by carbohydrate ingestion.
Objective: The objective was to examine the interaction between
TCF7L2 rs7903146 and dietary fat and carbohydrate [high-fat, low-
carbohydrate: 40–45% of energy as fat (HF); compared with low-
fat, high-carbohydrate: 20–25% of energy as fat (LF)] in obese
individuals’ responses to a 10-wk hypoenergetic diet (2600 kcal/d).
Design: European, obese participants (n = 771) were randomly
assigned to receive an HF or an LF diet. Body weight, fat mass
(FM), fat-free mass (FFM), waist circumference (WC), resting en-
ergy expenditure (REE), fasting fat oxidation in percentage of REE
(FatOx), homeostasis model assessed insulin release (HOMA-b),
and HOMA–insulin resistance (HOMA-IR) were determined at
baseline and after the intervention; 739 individuals were genotyped
for rs7903146.
Results: Average weight loss was 6.9 kg with the LF and 6.6 kg
with the HF (difference between diets, NS) diet. Among individuals
who were homozygous for the T-risk allele, those in the HF diet
group experienced smaller weight losses (Dweight) (2.6 kg; P =
0.009; n = 622), smaller DFFM (1.6 kg; P = 0.027; n = 609), smaller
DWC (3.3 cm; P = 0.010; n = 608), and a smaller DHOMA-IR (1.3
units; P = 0.004; n = 615) than did the LF diet group. For C allele
carriers, there were no differences between the HF and LF diet
groups. For the HF diet group, each additional T allele was associ-
ated with a reduced loss of FM (0.67 kg; P = 0.019; n = 609).
TCF7L2 rs7903146 was not associated with DREE, DFatOx,
DHOMA-b, or dropout.
Conclusion: Our results suggest that obese individuals who are
homozygous for the TCF7L2 rs7903146 T-risk allele are more sen-
sitive to LF than to HF weight-loss diets. Am J Clin Nutr
2010;91:472–9.
INTRODUCTION
It is of potential importance to identify individuals with
a genetic pattern that influences the response to weight reduction
therapy. The NUGENOB study [Nutrient-gene interaction in
human obesity: implication for dietary guidelines (contract no.
385 QLK1-CT-2000-00618; www.nugenob.org)] was a random-
ized trial comparing short-term high-fat (HF) and low-fat (LF)
hypoenergetic diets. After 10 wk, the average weight loss was
similar with the HF and LF diets: 6.6 and 6.9 kg, respectively
(mean difference: 0.3; 95% CI: 20.2, 0.8 kg) (1). Previously, 42
single nucleotide polymorphisms (SNPs) in 26 candidate genes
for obesity (2) and an SNP in the best confirmed locus for
common obesity (3) were examined in relation to weight loss.
The results suggested that the 42 candidate gene SNPs did not
have any major effect on weight reduction in the short term with
either the HF or LF hypoenergetic diet in obese individuals, but
that FTO rs9939609 interacts with the macronutrient composi-
tion of weight-loss diets—not in relation to weight loss itself but
in relation to drop out from the intervention and in relation to
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changes in resting energy expenditure (DREE), insulin release
(DHOMA-b), and insulin sensitivity (DHOMA-IR).
Transcription factor 7-like 2 (TCF7L2) was identified as
a type 2 diabetes (T2D) locus by the deCODE genetics group
(4), and this finding was subsequently confirmed in Europeans in
5 genome-wide association studies and also in other ethnic
groups (5). Of the 3 markers originally identified, rs7903146 is
the SNP most strongly associated to T2D (6, 7) and is consid-
ered, if not the causal variant itself, to be the closest known
correlate (7, 8). Weight gain does not seem to be part of the
causal pathway from rs7903146 to development to T2D (9), but
obesity seems to modify the association between rs7903146 and
T2D (10). In a study by Cauchi et al (10), the allelic odds ratio
(OR) of T2D was 1.89 (95% CI: 1.67. 2.14) for nonobese and
1.30 (95% CI: 1.14, 1.48) for obese individuals. The main ef-
fects of TCF7L2 rs7903146 on baseline values and changes in
BMI, insulin release, and insulin resistance (11) and on post-
absorptive REE and 3-h postprandial REE (12) was previously
analyzed in the NUGENOB cohort; no associations were found.
TCF7L2 is essential for transcription of the proglucagon gene
and thus for glucagon-like peptide 1 (GLP-1) synthesis (13). In
one study, no difference was found in either basal GLP-1 con-
centrations or in GLP-1 concentrations during an oral-glucose-
tolerance test (OGTT) between carriers and noncarriers of the
rs7903146 T-risk allele (14). Another study found non-
significantly lower GLP-1 concentrations during a mixed meal
in T-risk allele carriers than in noncarriers (15). Both studies
found a reduced insulinotropic effect of GLP-1 in T allele car-
riers. GLP-1 may contribute to body weight regulation in various
ways—through appetite (16, 17), adipose tissue metabolism (18,
19), and insulin signaling (20). Because its release is stimulated
differentially by fat and carbohydrate, GLP-1 concentrations are
higher after ingestion of fat than after ingestion of carbohydrate
in healthy (21) and insulin-resistant (22) individuals, it is pos-
sible that functional variants in TCF7L2 may alter the re-
sponsiveness to weight-loss diets differing in fat and
carbohydrate composition. We decided to examine whether
TCF7L2 rs7903146 is related to diet-induced weight loss and
associated phenotypes including possible interactions with the
macronutrient content of the weight-loss diet in the NUGENOB
cohort.
SUBJECTS AND METHODS
Participants and study design
The NUGENOB study was a randomized, parallel, 2-arm,
open-label, 10-wk dietary intervention (trial registration:
ISRCTN25867281) of 2 hypoenergetic diets with either a low
(LF) or high (HF) fat content. NUGENOB was a multicenter
study including 8 clinical centers in 7 European countries
[Sweden, Denmark, United Kingdom, Netherlands, Czech Re-
public, France (2 clinical centers), and Spain] and has been
described previously (www.nugenob.org) (1, 2).
Participants were recruited from May 2001 until September
2002 through the media, from waiting lists, ongoing population
studies, by self-referral, and referral from a general physician or
other clinical units and local obesity organizations. Inclusion
criteria were as follows: body mass index (BMI; in kg/m2)  30
and age 20–50 y. Exclusion criteria were as follows: weight
change .3 kg within 3 mo before the study start; hypertension,
diabetes or hyperlipidemia treated by drugs; untreated thyroid
disease; surgically or drug-treated obesity; pregnancy; partici-
pation in other trials; and alcohol or drug abuse.
The target macronutrient composition of the 2 diets was as
follows: LF diet (20–25% of total energy from fat, 15% from
protein, and 60–65% from carbohydrate) and HF diet (40–45% of
total energy from fat, 15% from protein, and 40–45% from
carbohydrate). Both diets were designed to provide 600 kcal/d
(2510 kJ/d) less than the individually estimated daily energy
requirement based on an initial resting metabolic rate multiplied
by 1.3. Subjects were given oral and written instructions relating
to these targets based on either a template (see details at www.
nugenob.org) or exchange system (23). Instructions were also
given to minimize differences between the 2 diets in other
components such as sources and type of fat, amount and type of
fiber, type of carbohydrate, fruit and vegetables, and meal fre-
quency and participants were requested to abstain from alcohol
consumption. Dietary instructions were reinforced weekly.
In total, 771 obese white Europeans (579 women) were in-
cluded and randomly assigned to receive 1 of the 2 intervention
diets by stratified block randomization. The randomization list
was computer generated at the coordinating center, and the block
size was unknown to the clinical centers. Informed written
consent was obtained before study participation, and the study
was approved by the ethics committee at each of the participating
centers.
Phenotypes
Before randomization to the weight-loss intervention and after
completion of the intervention, participants underwent a clinical
investigation protocol starting at 0800 after a 12-h overnight fast.
The first clinical investigation was preceded by a 3-d dietary run-
in period, during which participants had to keep to their habitual
diet and avoid excessive physical activity and alcohol con-
sumption. The second clinical investigation was conducted in the
10th week after the start of the dietary weight-loss intervention
program.
Anthropometric measures and body composition were
assessed after the subjects voided their bladder. Body weight was
measured on calibrated scales. Waist circumference (WC) was
measured while the participants were wearing only nonrestrictive
underwear. Body height was measured with a calibrated stadi-
ometer. The mean of 3 measurements was recorded for each
variable. Fat mass (FM) and fat-free mass (FFM) were assessed
by multifrequency bioimpedance (QuadScan 4000; Bodystat, Isle
of Man, British Isles).
REE and respiratory quotient (RQ) were measured by indirect
calorimetry with open-circuit ventilated hood systems routinely
used at each center for 30 min. The experimental room was kept
thermoneutral at 25 C. All equipment and procedures were
standardized for the different centers, and a standardized vali-
dation program was used to facilitate pooling of the results from
the different centers. Before the start of the study, validation was
assessed by using 10 alcohol-burning tests per center. Within-
subject variation was assessed by running repeated measure-
ments on the same day from 10 lean and/or obese fasting subjects
per center. The mean (6SD) variation in RQ was 0.6686 0.006.
Likewise the within-subject CV was 2.73 6 1.10 and 2.89 6
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1.19% for RQ and REE, respectively. REE was calculated ac-
cording to the equation of Weir (24). Fat oxidation (FatOx) was
calculated according to the equations of Frayn (25). In these
calculations, nitrogen excretion was assumed to be similar to
daily nitrogen intake. At the second clinical investigation day,
indirect calorimetry measurements on some of or all participants
completing the intervention were carried out in 6 of 8 centers
(Sweden, United Kingdom, Czech Republic, both centers in
France, and Spain). After participants rested supine for 15 min,
venous blood samples were drawn to determine fasting plasma
glucose and fasting plasma insulin. Plasma glucose concen-
trations (ABX Diagnostics, Montpellier, France) were measured
on a COBAS MIRA automated spectrophotometric analyzer
(Roche Diagnostica, Basel, Switzerland). Plasma insulin con-
centrations were measured with a double-antibody radioimmu-
noassay (Insulin RIA 100; Kabi-Pharmacia, Uppsala, Sweden).
Homeostasis model assessment was used to estimate insulin
release (HOMA-b) and insulin resistance (HOMA-IR) (26–28).
Genotyping
Samples of buffy coat were sent on dry ice to the Steno Di-
abetes Center in Copenhagen, where DNA was extracted.
Extracted DNA samples were diluted in Tris/EDTA buffer to
a stock DNA solution of 100 ng/lL and a working DNA solution
of 10 ng/lL. Stock solutions were stored at 280 C, and
working solutions were stored at 4C. DNA samples were stored
and handled in locations free of contaminating polymerase chain
reaction products.
Helgason et al (7) identified a variant of TCF7L2, HapA,
represented by haplotypes with rs10885406 A and rs7903146 C,
which was associated with BMI. In European individuals,
however, there is no difference in the associations of the
rs7903146 C allele and of the HapA haplotype with obesity (11).
In the present study, only rs7903146 was genotyped.
High-throughput genotyping of the rs7903146 variant was
performed by using the TaqMan SNP Genotyping Assays (Ap-
plied Biosystems, Foster City, CA). The polymerase chain re-
action primers and TaqMan probes were designed by Primer
Express and optimized according to the manufacturer’s protocol.
The genotype success rate was .98%. No duplicate samples
were made in the NUGENOB cohort to determine the error rate,
but the error rate was 0% when the same laboratory genotyped
rs7903146 in a previous study of 384 control and 384 T2D in-
dividuals (11). The rs7903146 allele frequencies were in Hardy-
Weinberg equilibrium (P = 0.91) (see Supplementary Table S1
under “Supplemental data” in the online issue).
Statistical methods
Examination of Hardy-Weinberg equilibrium was carried out
while taking into account center differences by summing up
Pearson chi-square statistics for each center and making com-
parisons with a chi-square distribution with 8 df.
First, general genetic models with no assumption of a specific
effect in individuals heterozygous and homozygous for the T
allele compared with noncarriers (null hypothesis) were ana-
lyzed. The results from these analyses were then used to decide
whether to proceed with analyzing models assuming a particular
effect of the T-risk allele compared with the noncarrier: domi-
nant effect (noncarrier = 0, heterozygous and homozygous = 1),
codominant effect (assessed as an additive effect: noncarrier = 0,
heterozygous = 1, homozygous = 2), or recessive effect (non-
carrier = 0, heterozygous = 0, homozygous = 1). Models ex-
amining the main effects of rs7903146 were made followed by
models examining the interaction between genotype and diet.
Changes (D) in body weight (kg), DFM (kg), DFFM (kg),
DWC (cm), DHOMA-b, DHOMA-IR, DREE (kcal/24 h) and
DFatOx (%) were calculated by subtracting measurements re-
corded immediately before randomization from the measure-
ment recorded at the completion of the intervention. Main
effects (with 95% CIs) of rs7903146 genotype (CC, CT, or TT)
and interactions between genotype and assigned hypoenergetic
diet (HF or LF) in relation to Dweight, DFM, DFFM, DWC,
DHOMA-b, DHOMA-IR, DREE, and DFatOx were estimated
by separate linear regression models for each outcome variable.
Drop-out was similarly analyzed in logistic regression models.
In models for changes in phenotypes, we controlled for re-
spective baseline values (linear; separate effect of weight, WC,
FM, and FFM for men and women; FM, HOMA-b, and HOMA-
IR were log transformed), age (linear in models of DFFM,
DHOMA-b, DHOMA-IR, DREE, and DFatOx; linear and
squared in models of Dweight, DFM, and DWC), sex, and center
(Gaussian random effect). When models for DFM and DFFM
were also adjusted for height and baseline weight, the same
results were obtained (data not shown). Models for DREE and
DFatOx were also adjusted for baseline FFM and DFFM. DWC
was additionally analyzed as the change in BMI-adjusted WC
residuals (the difference between residuals from regression
models with BMI at baseline as independent variable and WC at
baseline as dependent variable and residuals from regression
models with BMI after intervention as an independent variable
and WC after intervention as a dependent variable) [D(WC|
BMI)]. Models for DREE, DFatOx, and DHOMA-IR were also
performed while additionally adjusting for baseline FFM and
DFFM or for baseline FFM, baseline FM, DFFM, and DFM, but
this did not change the results from the analyses. Odds ratios
(ORs) for drop-out according to genotype and randomized diet
combined were analyzed with adjustment for baseline BMI
(linear), age (linear), sex, and center.
Assessments of main effects was conducted by including the
genotypes as covariates and as a separate covariate the diet group
to which the participants had been randomly assigned. Gene-diet
interactions were tested in analyses that also included a product
term for genotype · diet. The product term is then the genotype-
specific difference in mean Dweight, DFM, DFFM, DWC,
DHOMA-b, DHOMA-IR, DREE, and DFatOx, respectively—
adjusting as described above—between the LF and the HF and
then comparing the differences in mean Dweight, DFM, DFFM,
DWC, DHOMA-b, DHOMA-IR, DREE, and DFatOx, re-
spectively, for CT and/or TT with CC or CC and CT depending
on the assumed genetic model. Estimates from models including
a categorical genotype-diet variable are used to present com-
bined effects of genotype and diet when interactions are found.
The statistical software program STATA version 9.0 (Stata,
College Station, TX) was used for all statistical analyses. The
detectable genotype-diet interaction effect sizes for Dweight,
DFM, DFFM, DWC, and DHOMA-IR were estimated by using
QUANTO version 1.2 (29), and they were 2.82 kg for Dweight,
1.11 kg for DFM, 1.99 kg for DFFM, 3.72 cm for DWC, and
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1.31 for DHOMA-IR (see also Supplementary Table S2 under
“Supplemental data” in the online issue).
RESULTS
TCF7L2 rs7903146 was genotyped successfully in 739 out of
771 obese subjects. Overall, 117 of the successfully genotyped
subjects failed to complete the 10-wk weight-loss intervention,
but dropout was not associated with genotype (P = 0.49; n =
739).
Unadjusted mean values for anthropometric, body-composition,
and metabolic variables at baseline and the mean change from
baseline to after intervention are presented in Table 1 according
to genotype and diet. Pearson correlations partialled for age, sex,
and study center for all dependent variables are presented in
Supplementary Table S3 under “Supplemental data” in the on-
line issue.
The results of the regression analyses with no assumption
about genetic model are presented for all analyzed outcome
variables in Supplementary Table S4 under “Supplemental data”
in the online issue, which suggests that the associations between
the SNP and weight loss, DFFM, DWC, and DHOMA-IR are
better reflected by a recessive model than by the alternative
models (codominant or dominant models) and DFM by a co-
dominant model. The combined effects of genotype and diet on
Dweight, DFFM, DFM, DWC, and D-IR are presented in Figure
1. Among subjects who completed the intervention and for
whom TCF7L2 rs7903146 was genotyped, we found significant
interactions between genotype (TT compared with CC and CT)
and diet in relation to Dweight (P for interaction: 0.023; n =
622), DFM (per T-allele effect; P for interaction: 0.048; n =
609), DFFM (P for interaction: 0.032; n = 609), DWC (P for
interaction: 0.023; n = 608), and D-IR (P for interaction: 0.0025;
n = 615).
Weight loss
Mean Dweight was 26.81 kg. For subjects with the CC/CT
genotype, there was no difference in weight loss between the HF
and LF diet (P = 0.35). In individuals with the TT genotype,
weight loss was 2.57 kg smaller (P = 0.0088) with the HF than
with the LF diet. With the HF diet, weight loss was 2.08 kg
smaller (P = 0.010) for the TT genotype than for the CC/CT
genotype.
Loss of fat-free mass
Mean DFFM was 21.48 kg. For subjects with the CC/CT
genotype, there was no difference in DFFM between the HF and
LF diet groups (P = 0.94). For the TT genotype, loss of FFM was
1.55 kg smaller (P = 0.027) with the HF than with the LF diet.
With the HF diet, loss of FFM was 1.31 kg smaller (P = 0.022)
with the TT genotype than with the CC/CT genotype.
Loss of fat mass
Mean DFM was 25.35 kg. For subjects randomly assigned to
the HF diet, loss of FM decreased by 0.67 kg for each additional
T allele (P = 0.019). With the LF diet, the T allele was not as-
sociated with DFM (P = 0.73). For subjects with the CT and TT
genotypes, loss of FM was 0.63 and 1.39 kg smaller, re-
spectively (P = 0.031 and P = 0.021), with the HF than with the
LF diet in the codominant model.
Decrease in waist circumference
Mean DWC was 26.33 cm. For subjects with the CC/CT
genotype, there was no difference in DWC between the HF and
LF diets (P = 0.43). For the TT genotype, the decrease in WC
was 3.33 cm smaller (P = 0.010) with the HF than with the LF
diet. With the HF diet, the decrease in WC was 2.40 cm smaller
(P = 0.024) in subjects with the TT genotype than with the CC/
CT genotype. We found no effect of TCF7L2 rs7903146 or diet
on D(WC|BMI).
Decrease in insulin resistance and release
Mean DHOMA-IR was 20.31 units. For subjects with the
CC/CT genotype, there was no difference in DHOMA-IR be-
tween the HF and LF diet groups (P = 0.42). For the TT geno-
type, the decrease in HOMA-IR was 1.33 units smaller (P =
0.004) with the HF than with the LF diet. With the HF diet, the
decrease in HOMA-IR was 1.26 units smaller (P = 0.001) for the
TT genotype than for the CC/CT genotype. We found no effect of
TCF7L2 rs7903146 on DHOMA-b. Mean DHOMA-b among
successfully genotyped participants completing the intervention
was 27.83 units.
Decrease in REE and fat oxidation
We found no effect of TCF7L2 rs7903146 on DREE or
DFatOx. Among successfully genotyped participants completing
the intervention, REE decreased on average by 114.8 kcal/24 h,
whereas FatOx increased by 2.3% points from 46.7% REE to
49.0% REE.
DISCUSSION
In the present weight-loss intervention study, we found sta-
tistically significant interactions between TCF7L2 rs7903146
genotype and the macronutrient content of the hypoenergetic
diet (HF and LF) in relation to changes in 5 (Dweight, DFFM,
DFM, DWC, and DHOMA-IR) of 8 investigated obesity-related
phenotypes.
Some, but not all, previous studies found that the T-risk allele
at TCF7L2 rs7903146 associated with estimates of decreased
insulin release (30–33) and surrogate measures of decreased
insulin sensitivity (30). In the present study, rs7903146 was
associated with DHOMA-IR and with changes in anthropo-
metric and body-composition variables, but not with DHOMA-
b. It is possible that this inconsistency with the literature was
due to the fact that the present study addressed diet-induced
weight loss in obese patients, showing effects of the gene variant
that differ from those inducing the elevated risk of T2D as
mentioned in the Introduction (10).
The effects were fairly consistent for the 5 phenotypes,
although the effects on DFM fit better with a codominant
genetic model, whereas effects on Dweight, DFFM, DWC,
and DHOMA-IR were found in recessive models. In most
studies of TCF7L2 rs7903146 and T2D, the genetic effect
appeared to be codominant (11), although other studies sug-
gest a recessive (31) or dominant (33) effect. The biological
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TABLE 1
Unadjusted phenotype baseline values and changes during the 10-wk randomized intervention according to genotype at TCF7L2 rs7903146 and type of diet1
CC CT TT
P for main
effect of
rs79031462
P for
gene-diet
interaction2Genotype at rs7903146
LF
(n = 168)
HF
(n = 149)
LF
(n = 125)
HF
(n = 134)
LF
(n = 29)
HF
(n = 17)
BMI (kg/m2)
Baseline 36.0 6 5.0 35.5 6 4.4 35.0 6 4.8 35.5 6 4.7 34.4 6 4.0 36.7 6 5.5
Change 22.5 6 1.2 22.4 6 1.3 22.4 6 1.1 22.3 6 1.1 22.5 6 1.4 21.7 6 1.1
Body weight (kg)
Baseline 101.6 6 17.0 100.9 6 14.9 98.7 6 16.5 99.5 6 15.7 94.5 6 11.8 104.0 6 17.1
Change 27.1 6 3.4 26.9 6 3.7 26.8 6 3.2 26.6 6 3.2 26.9 6 4.0 24.8 6 3.3 0.193 0.0233
Fat-free mass (kg)
Baseline 60.1 6 11.9 60.0 6 11.3 59.1 6 11.5 58.9 6 11.6 56.2 6 9.3 60.2 6 10.1
Change 21.6 6 2.4 21.3 6 2.7 21.3 6 2.4 21.7 6 1.9 21.6 6 2.3 20.4 6 2.2 0.333 0.0323
Fat mass (kg)
Baseline 41.7 6 12.1 41.2 6 10.9 39.6 6 12.2 40.9 6 10.3 38.5 6 7.4 43.8 6 14.8
Change 25.4 6 3.3 25.6 6 3.4 25.5 6 3.1 24.9 6 2.7 25.4 6 3.4 24.4 6 3.2 0.204 0.0484
Waist circumference (cm)
Baseline 107 6 13.1 106 6 12.4 105 6 12.8 106 6 12.3 103 6 11.2 108 6 14.1
Change 26.7 6 4.4 26.3 6 4.7 26.4 6 4.2 26.0 6 4.0 26.8 6 6.1 24.2 6 4.8 0.443 0.0233
BMI-adjusted waist
circumference (cm)
Baseline 0.2 6 9.3 20.4 6 9.1 20.4 6 9.3 20.1 6 9.0 21.1 6 10.1 20.5 6 10.1
Change 0.1 6 3.6 0.2 6 3.9 0.2 6 3.7 0.4 6 3.2 0.0 6 4.9 0.9 6 4.0 0.605 0.705
Fasting plasma glucose (mmol/L)
Baseline 5.5 6 1.4 5.3 6 0.6 5.3 6 0.6 5.5 6 0.7 5.2 6 0.4 5.6 6 1.3
Change 20.1 6 0.5 20.1 6 0.5 20.1 6 0.5 20.2 6 0.5 20.2 6 0.3 0.01 6 0.7
Fasting serum insulin (lU/mL)
Baseline 10.4 6 5.9 10.5 6 7.2 9.2 6 5.5 10.7 6 6.1 9.2 6 5.6 10.0 6 5.3
Change 21.0 6 5.6 21.1 6 5.7 21.2 6 4.2 21.6 6 5.5 21.2 6 4.7 2.6 6 9.8
HOMA-b
Baseline 117 6 63.2 114 6 70.7 106 6 62.0 111 6 60.0 115 6 78.6 105 6 53.7
Change 28.5 6 61.6 26.3 6 55.1 211.3 6 47.4 29.4 6 55.1 27.8 6 59.7 25.2 6 82.0 0.175,6 0.175,6
HOMA-IR
Baseline 2.6 6 2.1 2.6 6 1.9 2.2 6 1.5 2.7 6 1.8 2.2 6 1.3 2.7 6 2.2
Change 20.2 6 1.9 20.3 6 1.6 20.3 6 1.1 20.5 6 1.5 20.4 6 1.1 0.8 6 2.7 0.123,6 0.00253,6
REE (kcal/24 h)7
Baseline 1878 6 335 1886 6 314 1878 6 315 1863 6 314 1818 6 262 1950 6 236
Change 2109 6 156 2117 6 182 2101 6 190 2128 6 174 2108 6 170 2137 6 194 0.745 0.945
Fasting FatOx (kcal/24 h)7
Baseline 886 6 398 875 6 401 878 6 368 881 6 337 893 6 192 938 6 221
Change 223 6 378 12 6 410 232 6 458 1 6 292 297 6 351 260 6 281
Fasting FatOx (% of REE)7
Baseline 46.4 6 18.0 46.1 6 18.1 46.0 6 15.9 47.2 6 15.8 50.1 6 12.4 48.1 6 10.0
Change 2.2 6 20.9 4.1 6 19.6 0.5 6 23.1 3.4 6 15.0 23.5 6 18.5 0.6 6 12.9 0.925,6 0.495,6
1 All values are means 6 SDs. Baseline values are for those who completed the intervention. Change was defined as the value at week 10 minus the
baseline value. HF, high-fat, low-carbohydrate hypoenergetic diet (2600 kcal/d); LF, low-fat, high-carbohydrate hypoenergetic diet (2600 kcal/d); HOMA-
IR, homeostasis model assessed insulin resistance; HOMA-b, homeostasis model assessed insulin release; FatOx, fat oxidation as a percentage of resting
energy expenditure; REE, resting energy expenditure.
2 P values from linear regression analyses carried out for the variables relevant for the objective of the study: change (D) in weight, Dfat-free mass (FFM),
Dfat mass (FM), Dwaist circumference (WC), DHOMA-b, DHOMA-IR, DREE, and DFatOx. Adjusted for baseline weight (linear; separate effect for men and
women), FFM (linear; separate effect for men and women), FM (log transformed; linear; separate effect for men and women), WC (linear; separate effect for
men and women), HOMA-b (logarithm transformed; linear), HOMA-IR (logarithm transformed; linear), REE (linear), and FatOx (linear), respectively, along
with age (linear in models of DFFM, DHOMA-b, DHOMA-IR, REE, and DFatOx; linear and squared in models of Dweight, DFM, and DWC), sex, and center
(Gaussian random effect).
3 Genetic model: recessive.
4 Genetic model: codominant.
5 No assumption of genetic model.
6 Models for DHOMA-IR were also performed with additional adjustment for baseline FFM and DFFM or for baseline FFM, baseline FM, DFFM and
DFM, but this did not change the results from the analyses.
7 After the intervention, REE and FatOx were measured in’66% of the subjects who completed the intervention. (CC, LF: n = 110; CC, HF: n = 98; CT,
LF: n = 69; CT, HF: n = 85; TT, LF: n = 19; TT, HF: n = 13).
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processes leading to T2D may, however, be different from
those investigated here. The figures for Dweight and DWC are
almost identical; 1-kg differences in Dweight mirrored as
1-cm difference in DWC. The TCF7L2 variant and diet had
no effect on D(WC|BMI).
Considering that ’75% of the mean weight loss in the whole
group was loss of FM and ’25% was loss of FFM, the differ-
ence in DFFM explained a relatively large part (’50%) of the
difference in Dweight (’2.6 kg) between the LF and HF diets
for the TT genotype.
FIGURE 1. Combined effects of TCF7L2 rs7903146 genotype (CC, CT, and TT) and dietary fat and carbohydrate [high-fat, low-carbohydrate (high fat)
compared with low-fat, high-carbohydrate (low fat) hypoenergetic diets] on changes in weight (Dweight), fat-free mass (DFFM), fat mass (DFM), waist
circumference (DWC), and homeostasis model assessed insulin resistance (DHOMA-IR) from linear regression models. The genetic models were recessive
(CC/CT compared with TT) for Dweight, DFFM, DWC, and DHOMA-IR and codominant (additive effect of the T allele) for DFM. For Dweight, DFFM, DWC,
and DHOMA-IR, 95% CIs are for comparison with the CC/CT genotype with the low-fat diet. For DFM, 95% CIs are for comparison with the genotype with
one less T-risk allele within each diet group. Values in the comparison group are the mean values of that genotype-diet group. Differences in Dweight, DFFM,
DFM, DWC, and DHOMA-IR between one genotype-diet group and the reference group are from linear regressions adjusted for baseline weight (linear;
separate effect for men and women), baseline FFM (linear; separate effect for men and women), baseline FM (logarithm transformed; linear; separate effect
for men and women), baseline WC (linear; separate effect for men and women), and baseline HOMA-IR (logarithm transformed; linear), respectively, along
with age (linear and squared for Dweight, DFM, DWC; linear for DFFM and DHOMA-IR), sex, and center (Gaussian random effect). The analysis of
DHOMA-IR was also performed while additionally adjusting for baseline FFM and DFFM or for baseline FFM, baseline FM, DFFM and DFM; the interaction
remained. %E, percentage of energy.
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The effects of TCF7L2 rs7903146 on weight loss in the
present study were larger than any effect found of 43 SNPs in 27
genes (including FTO) previously analyzed in relation to weight
loss in NUGENOB (2, 3), where the largest significant differ-
ence in weight loss between HF and LF diets was 1.7 kg for
KCNJ11 rs5219 (2). No previous associations between TCF7L2
variants and weight loss or related phenotypes were found, but
our finding of greater weight loss and increased insulin sensi-
tivity depending on genotype and diet may be important for T2D
prevention. Because we previously found effects of a variant in
FTO on DHOMA-b, DHOMA-IR, and DREE in the NUGENOB
cohort (3) and because these variables would be related to or
affected by Dweight, DFFM, and DWC, it would be interesting
to examine possible interactions between variants in FTO and
variants in TCF7L2 in a larger data set. Previous studies have
found interactions between TCF7L2 variants and dietary whole-
grain products (34), glycemic index, glycemic load (35), and
polyunsaturated fatty acids (36) in relation to risk of T2D and
atherogenic dyslipidemia. The findings of our study add to the
evidence that some TCF7L2 variants make individuals sensitive
to the carbohydrate and fat components of the diet. Elucidation
of which specific dietary components and which step in the
TCF7L2 pathway is implicated is a challenge for future re-
search. One possibility is the GLP-1 pathway.
TCF7L2 was found to be essential for GLP-1 synthesis in
a gut endocrine cell line in response to stimulation with lithium
(13), and the insulinotropic action of GLP-1 is reduced in
rs7903146 T-risk allele carriers (14, 15). Differential GLP-1
release stimulated by fat and carbohydrate together with
TCF7L2 rs7903146 altering GLP-1 action may explain the
observed interaction between the rs7903146 genotype and
macronutrient composition. Part of the effects we observed
may be related to the lack of GLP-1–mediated effects on sa-
tiety and/or adipose tissue metabolism affecting fatty acid
handling. Meal ingestion is the primary physiologic stimulus
for GLP-1 secretion (37), and, because the response is greater
after ingestion of fat than of carbohydrate (21, 22), it is plau-
sible that the adverse effect of risk variants of TCF7L2 are
more pronounced with an HF than with an LF diet. Recent data
indicate that increased endogenous GLP-1 release reduces fatty
acid flux from adipose tissue during fasting (18) and increases
postprandial lipolysis and FatOx, ie, affects adipose tissue and
skeletal muscle metabolism (19). It can be speculated that
subjects with the TCF7L2 variant may take longer to adapt the
postprandial FatOx to the relatively high-fat diet, irrespective
of the absence of effects on fasting FatOx, which leads to
a less-negative fat energy balance and less weight loss only
with the high-fat diet. In addition, GLP-1 may also directly
affect lipid absorption at the gut level and may directly affect
insulin signaling at the adipose tissue level (20).
It is possible that the participants changed their behaviors
during the trial (eg, physical activity and smoking). Because these
other behaviors cannot be properly controlled for, we cannot
exclude the possibility that such changes might explain part of the
effects of the intervention. If change in behavior was different
between the 2 diet groups, it could explain the observed inter-
actions. On the other hand, we do find it unlikely that the ten-
dency to make such changes independent of the dietary
intervention was skewed between the 2 randomized groups be-
cause of the fairly large sample size.
Analyzing the allocated diet (HF or LF) rather than the actual
diet may have obscured the associations examined in the present
study. Although average weight loss was as expected, which
indicated that the participants, on average, complied with the
600 kcal/d energy deficit, the interindividual variation in weight
loss suggested that not all subjects complied fully with the energy
restriction—some individuals had a higher energy intake and
others a lower energy intake than targeted (1). Similarly, con-
cerning compliance with fat and carbohydrate intakes with the
HF and LF diets, the differences in changes in blood lipids
between diets were as expected, but there were considerable
interindividual differences in reported fat and carbohydrate
composition within both diets (2). However, the use of reported
intakes has its own limitations, eg, potential misreporting, which
may challenge the advantage of the randomized design.
In the present study, multiple tests were conducted. One SNP
was analyzed in relation to 9 outcomes (dropout from in-
tervention, weight loss, loss of FM, loss of FFM, and decreases in
WC, insulin secretion, insulin release, REE, and FatOx). Inter-
actions as well as main effects were investigated. In total, 18
associations between the SNP and the outcome variables were
analyzed. Because the multiple statistical testing done for the
TCF7L2 variant is not analogous to repeated testing of the same
null hypothesis multiple times and because the choice of ana-
lyzing these variants is clearly hypothesis-driven, it can be ar-
gued that adjustment for multiple testing is not required.
However, if such a correction were made by the very conser-
vative Bonferroni method, only P values ,0.0028 would be
statically significant. As an alternative to the Bonferroni cor-
rection, we have considered the expected proportions of type I
errors, which is a 0.9 false-positive association when analyzing
18 associations.
Apart from TCF7L2 rs7903146 the effects of 48 SNPs in 30
genes have been studied in relation to changes in anthropometric
and/or metabolic variables during the NUGENOB weight loss
intervention (2, 3) (unpublished data for 5 SNPs in 3 genes,
2008 and 2009) and more SNPs will follow. If the analyses of all
these SNPs are considered, repeated testing of the same null
hypothesis multiple times all nominally significant associations
would be expected to be nonsignificant.
Taking into account that the statistical testing has an element of
post hoc analysis by choosing the recessive model on the basis of
the observed data, our results must be interpreted with caution
and be considered only as leads to further studies of the inter-
actions between the function of the TCF7L2 gene and diet
composition.
Although the CIs of the present study are fairly narrow, it
should be noted that, because of the size and thus the power of the
study, it is possible that we have missed some clinically relevant
effects of TCF7L2 rs7903146.
Previous analyses comparing the 2 diets in the NUGENOB
study, but not including genetic factors, led to the conclusion that
the LF and HF hypoenergetic diet produced similar mean weight
loss and that both diets produced favorable changes in fasting
insulin and glucose (1). The effect of TCF7L2 rs7903146 on
weight loss, which was also reflected in loss of FFM, loss of FM,
and a decrease in WC and the effect we found on HOMA-IR
suggest that an LF hypoenergetic diet may be preferable to an
HF hypoenergetic diet for healthy obese carriers of the TCF7L2
rs7903146 T-risk allele who wish to lose weight and may reduce
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their risk of developing T2D. However, because there have been
no previous reports of TCF7L2 rs7903146-macronutrient inter-
actions in relation to weight status or weight loss, these findings
needs to be replicated in a different population.
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